WIXOM, Mich., Sept. 19, 2011 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ERSD), chronic kidney disease (CKD), and iron deficiency anemia, announced today that it has hired Annamaria T. Kausz, M.D., M.S. as Vice President of Drug Development and Medical Affairs. Dr. Kausz will be responsible for leading the new drug application (NDA) submission for Rockwell’s Soluble Ferric Pyrophosphate (SFP) upon completion of its on-going Phase III CRUISE studies, as well as overseeing all aspects of clinical research and development for SFP and new drug indications. Dr. Kausz replaces Dr. Richard Yocum.
